Recent publications
Publications
-
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
Part of Frontiers in Pharmacology, 2023.
DOI for Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development Download full text (pdf) of Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
-
Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
Part of Clinical Pharmacology and Therapeutics, p. 851-858, 2023.
DOI for Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study Download full text (pdf) of Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
-
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
Part of Clinical and Translational Science, p. 73-84, 2023.
DOI for Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors Download full text (pdf) of Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
-
Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
Part of CPT, p. 154-167, 2023.
DOI for Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity Download full text (pdf) of Rituximab pharmacokinetic and pharmacokinetic-pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
-
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
Part of Frontiers in Pharmacology, 2023.
DOI for Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development Download full text (pdf) of Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
-
Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
Part of International Journal of Antimicrobial Agents, 2023.
DOI for Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin Download full text (pdf) of Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
-
Clinical standards for the management of adverse effects during treatment for TB
Part of The International Journal of Tuberculosis and Lung Disease, p. 506-519, 2023.
DOI for Clinical standards for the management of adverse effects during treatment for TB Download full text (pdf) of Clinical standards for the management of adverse effects during treatment for TB
-
Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
Part of Cytokine, 2023.
DOI for Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli Download full text (pdf) of Predicting cytokine kinetics during sepsis; a modelling framework from a porcine sepsis model with live Escherichia coli
-
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
Part of Thrombosis and Haemostasis, p. 317-325, 2023.
DOI for Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A Download full text (pdf) of Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
-
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
Part of CPT, p. 977-987, 2023.
DOI for Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy Download full text (pdf) of Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
-
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
Part of Advances in Therapy, p. 3739-3750, 2023.
DOI for Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients Download full text (pdf) of Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
-
Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials
Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 297-314, 2023.
DOI for Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials Download full text (pdf) of Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials
-
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
Part of iScience, 2023.
DOI for Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium Download full text (pdf) of Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium
-
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii
Part of Microbiology Spectrum, 2023.
DOI for Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii Download full text (pdf) of Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii
-
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
Part of Journal of Antimicrobial Chemotherapy, p. 934-943, 2022.
-
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Part of Clinical Cancer Research, p. 1363-1371, 2022.
DOI for Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Download full text (pdf) of Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
-
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
Part of Pharmaceutics, 2022.
DOI for Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis Download full text (pdf) of Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial
Part of American Journal of Respiratory and Critical Care Medicine, p. 1228-1235, 2022.
-
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
Part of Clinical Microbiology and Infection, p. 73-78, 2022.
-
Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia
Part of International Journal of Antimicrobial Agents, 2022.
-
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Part of Clinical Microbiology and Infection, p. 448.e1-448.e7, 2022.
DOI for Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics Download full text (pdf) of Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
-
Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
Part of CPT, p. 991-1001, 2022.
DOI for Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application Download full text (pdf) of Finding the right hazard function for time-to-event modeling: A tutorial and Shiny application
-
Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
Part of Pharmaceutical research, p. 1779-1787, 2022.
DOI for Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients Download full text (pdf) of Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
-
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
Part of Pharmaceutics, 2022.
DOI for Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin Download full text (pdf) of Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
-
Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
Part of Antibiotics, 2022.
DOI for Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings Download full text (pdf) of Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings
-
A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
Part of CPT, p. 628-639, 2022.
DOI for A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study Download full text (pdf) of A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
-
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
Part of Scientific Reports, 2022.
DOI for Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance Download full text (pdf) of Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
-
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma
Part of Journal of clinical pharmacology, p. 905-917, 2022.
DOI for Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma Download full text (pdf) of Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients With Severe Asthma
-
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Part of Journal of Infectious Diseases, p. 1876-1885, 2022.
DOI for Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data Download full text (pdf) of Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
-
Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue: Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
Part of Pharmaceutical research, p. 1633-1643, 2022.
-
Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
Part of Frontiers in Microbiology, 2022.
DOI for Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections Download full text (pdf) of Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
-
Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
Part of Clinical Microbiology and Infection, p. 1367-1374, 2022.
DOI for Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia Download full text (pdf) of Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia
-
Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
Part of Journal of Antimicrobial Chemotherapy, p. 2718-2728, 2022.
DOI for Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose Download full text (pdf) of Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
-
Research priorities towards precision antibiotic therapy to improve patient care
Part of LANCET MICROBE, p. e795-e802, 2022.
DOI for Research priorities towards precision antibiotic therapy to improve patient care Download full text (pdf) of Research priorities towards precision antibiotic therapy to improve patient care
-
Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia
Part of Journal of Antimicrobial Chemotherapy, p. 2479-2488, 2022.
-
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
Part of CPT, p. 1628-1637, 2022.
DOI for Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug Download full text (pdf) of Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
-
Pharmacometrics in tuberculosis: progress and opportunities
Part of International Journal of Antimicrobial Agents, 2022.
DOI for Pharmacometrics in tuberculosis: progress and opportunities Download full text (pdf) of Pharmacometrics in tuberculosis: progress and opportunities
-
Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
Part of International Journal of Antimicrobial Agents, 2022.
DOI for Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects Download full text (pdf) of Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
-
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
Part of eClinicalMedicine, 2022.
DOI for Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial Download full text (pdf) of Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double- blind, randomised, controlled, phase 3 trial
-
Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
Part of BMJ Open, 2022.
DOI for Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival Download full text (pdf) of Study protocol for locoregional precision treatment of hepatocellular carcinoma with transarterial chemoembolisation (TACTida), a clinical study: idarubicin dose selection, tissue response and survival
-
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
Part of BMJ Open, 2022.
DOI for Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP) Download full text (pdf) of Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
-
A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations
Part of Clinical Pharmacology and Therapeutics, p. 416-423, 2021.
-
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
Part of Clinical Pharmacology and Therapeutics, p. 867-891, 2021.
DOI for Model-Informed Drug Development for Anti-Infectives: State of the Art and Future Download full text (pdf) of Model-Informed Drug Development for Anti-Infectives: State of the Art and Future
-
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
Part of BMC Infectious Diseases, 2021.
DOI for Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity Download full text (pdf) of Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
-
Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
Part of Pharmaceutical research, p. 593-605, 2021.
DOI for Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety Download full text (pdf) of Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
-
CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
Part of CPT, p. 649-657, 2021.
DOI for CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision Download full text (pdf) of CPT: Pharmacometrics & Systems Pharmacology - Inception, Maturation, and Future Vision
-
Pivotal Role of Translation in Anti-Infective Development
Part of Clinical Pharmacology and Therapeutics, p. 856-866, 2021.
DOI for Pivotal Role of Translation in Anti-Infective Development Download full text (pdf) of Pivotal Role of Translation in Anti-Infective Development